Defining severe asthma – an approach to find new therapies

Article, Unknown English OPEN
Nanzer, Alexandra M. ; Menzies-Gow, Andrew (2014)
  • Publisher: Co-Action Publishing
  • Journal: European Clinical Respiratory Journal, volume 1 (eissn: 2001-8525)
  • Related identifiers: doi: 10.3402/ecrj.v1.24356, doi: 10.3402/ecrj.v1i0.24356, pmc: PMC4629770
  • Subject: Review Article | phenotypes | comorbidities | new biological treatments | severe asthma | Severe asthma, co-morbidities, phenotypes, new biological treatments

Asthma is a chronic inflammatory disease that has reached epidemic proportions worldwide. It is treatable in the majority of patients, but there is no cure. Moreover, a proportion of patients suffer from severe, difficultto- control disease with daily symptoms and high morbidity, making it imperative that we continue to improve our understanding of the underlying mechanisms of this disease. Severe asthma is a heterogeneous condition. A systematic approach to identify specific asthma phenotypes, including clinical characteristics and inflammatory processes, is the first step toward individualized, logical therapy. This review focuses on the need to characterize severe asthma phenotypes and on novel, targeted molecular treatment options currently under development.Keywords: severe asthma; comorbidities; phenotypes; new biological treatments(Published: 5 June 2014)Citation: European Clinical Respiratory Journal 2014, 1: 24356 - http://dx.doi.org/10.3402/ecrj.v1.24356
  • References (95)
    95 references, page 1 of 10

    1. Martinez FD, Vercelli D. Asthma. Lancet. 2013; 382: 1360 72.

    2. BTS/SIGN. British guideline on the management of asthma. A national clinical guideline. 2008. British Thoracic Society and Scottish Intercollegiate Guidelines Network (SIGN). Available from: http://www.sign.ac.uk/guidelines/fulltext/101/index.html (Revised January 2012).

    3. Bateman ED, Boushey HA, Bousquet J, Busse WW, Clark TJ, Pauwels RA, et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med. 2004; 170: 836 44.

    4. Robinson DS, Campbell DA, Durham SR, Pfeffer J, Barnes PJ, Chung KF. Systematic assessment of difficult-to-treat asthma. Eur Respir J. 2003; 22: 478 83.

    5. Heaney LG, Conway E, Kelly C, Johnston BT, English C, Stevenson M, et al. Predictors of therapy resistant asthma: outcome of a systematic evaluation protocol. Thorax. 2003; 58: 561 6.

    6. Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014; 43: 343 73.

    7. Moore WC. Update in asthma 2007. Am J Respir Crit Care Med. 2008; 177: 1068 73.

    8. Chung SD, Chen PY, Lin HC, Hung SH. Comorbidity profile of chronic rhinosinusitis: a population-based study. The Laryngoscope. 2014. doi: 10.1002/lary.24581.

    9. Choi JH, Kim MA, Park HS. An update on the pathogenesis of the upper airways in aspirin-exacerbated respiratory disease. Curr Opin Allergy Clin Immunol. 2014; 14: 1 6.

    10. Harding SM, Allen JE, Blumin JH, Warner EA, Pellegrini CA, Chan WW. Respiratory manifestations of gastroesophageal reflux disease. Ann N Y Acad Sci. 2013; 1300: 43 52.

  • Metrics
    No metrics available
Share - Bookmark